RCUS Latest Headlines

Arcus Biosciences: Buy Rating Reaffirmed as Safety Profile Supports Risk/Reward; 12-Month Price Target Maintained at $50

at www.tipranks.com (Mon, 26-Oct 5:35 AM)

Arcus Biosciences Completes $269 Million Common Stock Offering

at www.tipranks.com (Fri, 23-Oct 4:30 PM)

Arcus Biosciences prices 14.29M-share offering at $17.50, with a 30-day option for 2.14M more

Market Chameleon (Thu, 22-Oct 7:36 AM)

At a glance: stocks gapping down premarket

at seekingalpha.com (Thu, 22-Oct 7:34 AM)

Arcus Biosciences prices $250M public offering at $17.50 per share

at seekingalpha.com (Thu, 22-Oct 5:18 AM)

Arcus Biosciences announces public stock offering

at seekingalpha.com (Wed, 21-Oct 4:24 PM)

Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Arcus Biosciences (RCUS) and Incyte (INCY)

at www.tipranks.com (Wed, 21-Oct 8:02 AM)

Arcus highlights nearly three-year median overall survival signal for casdatifan in late-line kidney cancer

Market Chameleon (Tue, 20-Oct 10:26 AM)

Arcus spotlights ARC-20 kidney cancer data, including a 35-month median overall survival in late-line casdatifan monotherapy

Market Chameleon (Tue, 20-Oct 8:43 AM)